Cargando…

Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis

Psoriasis is associated with cardiometabolic and cardiovascular diseases. Biologic therapy targeting tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17 may improve not only psoriasis but also cardiometabolic diseases. We retrospectively evaluated whether biologic therapy improved various...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagino, Teppei, Saeki, Hidehisa, Fujimoto, Eita, Kanda, Naoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004419/
https://www.ncbi.nlm.nih.gov/pubmed/36902720
http://dx.doi.org/10.3390/jcm12051934
_version_ 1784904828001976320
author Hagino, Teppei
Saeki, Hidehisa
Fujimoto, Eita
Kanda, Naoko
author_facet Hagino, Teppei
Saeki, Hidehisa
Fujimoto, Eita
Kanda, Naoko
author_sort Hagino, Teppei
collection PubMed
description Psoriasis is associated with cardiometabolic and cardiovascular diseases. Biologic therapy targeting tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17 may improve not only psoriasis but also cardiometabolic diseases. We retrospectively evaluated whether biologic therapy improved various indicators of cardiometabolic disease. Between January 2010 and September 2022, 165 patients with psoriasis were treated with biologics targeting TNF-α, IL-17, or IL-23. The patients’ body mass index; serum levels of HbA1c, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol, triglyceride (TG), and uric acid (UA); and systolic and diastolic blood pressures were recorded at weeks 0, 12, and 52 of the treatment. Baseline psoriasis area and severity index (week 0) positively correlated with TG and UA levels but negatively correlated with HDL-C levels, which increased at week 12 of IFX treatment compared to those at week 0. UA levels decreased at week 12 after ADA treatment compared with week 0. HDL-C levels decreased 52 weeks after IXE treatment. In patients treated with TNF-α inhibitors, HDL-C levels increased at week 12, and UA levels decreased at week 52, compared to week 0. Thus, the results at two different time points (at weeks 12 and 52) were inconsistent. However, the results still indicated that TNF-α inhibitors may improve hyperuricemia and dyslipidemia.
format Online
Article
Text
id pubmed-10004419
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100044192023-03-11 Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis Hagino, Teppei Saeki, Hidehisa Fujimoto, Eita Kanda, Naoko J Clin Med Article Psoriasis is associated with cardiometabolic and cardiovascular diseases. Biologic therapy targeting tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17 may improve not only psoriasis but also cardiometabolic diseases. We retrospectively evaluated whether biologic therapy improved various indicators of cardiometabolic disease. Between January 2010 and September 2022, 165 patients with psoriasis were treated with biologics targeting TNF-α, IL-17, or IL-23. The patients’ body mass index; serum levels of HbA1c, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol, triglyceride (TG), and uric acid (UA); and systolic and diastolic blood pressures were recorded at weeks 0, 12, and 52 of the treatment. Baseline psoriasis area and severity index (week 0) positively correlated with TG and UA levels but negatively correlated with HDL-C levels, which increased at week 12 of IFX treatment compared to those at week 0. UA levels decreased at week 12 after ADA treatment compared with week 0. HDL-C levels decreased 52 weeks after IXE treatment. In patients treated with TNF-α inhibitors, HDL-C levels increased at week 12, and UA levels decreased at week 52, compared to week 0. Thus, the results at two different time points (at weeks 12 and 52) were inconsistent. However, the results still indicated that TNF-α inhibitors may improve hyperuricemia and dyslipidemia. MDPI 2023-03-01 /pmc/articles/PMC10004419/ /pubmed/36902720 http://dx.doi.org/10.3390/jcm12051934 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hagino, Teppei
Saeki, Hidehisa
Fujimoto, Eita
Kanda, Naoko
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
title Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
title_full Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
title_fullStr Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
title_full_unstemmed Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
title_short Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
title_sort effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004419/
https://www.ncbi.nlm.nih.gov/pubmed/36902720
http://dx.doi.org/10.3390/jcm12051934
work_keys_str_mv AT haginoteppei effectsofbiologictherapyonlaboratoryindicatorsofcardiometabolicdiseasesinpatientswithpsoriasis
AT saekihidehisa effectsofbiologictherapyonlaboratoryindicatorsofcardiometabolicdiseasesinpatientswithpsoriasis
AT fujimotoeita effectsofbiologictherapyonlaboratoryindicatorsofcardiometabolicdiseasesinpatientswithpsoriasis
AT kandanaoko effectsofbiologictherapyonlaboratoryindicatorsofcardiometabolicdiseasesinpatientswithpsoriasis